News

Yazen secures €50 million

New study finds comparable 18-month weight loss with oral and injectable semaglutide

New oral treatments could lower the barrier to obesity care and make treatment accessible to more people.

Yazen Founder on the Lejonkulan Podcast: The Growth Journey and the Future of Obesity Care

Key Takeaways from the Economist Enterprise Obesity & Metabolic Health Summit 2026

New real-world data from over 40,000 patients show that digital obesity care produces significant and sustained weight loss even with low medication doses.

Ahead of World Obesity Day on 4 March, Yazen is sharing new findings from internal patient data, revealing that shame and stigma remain major barriers to obesity care — even as effective medical treatments become more widely available.

UK employers are increasingly considering weight-loss support as part of employee benefits, as new Yazen patient data links GLP-1 treatment to reduced sick days and improved workplace performance.

In 2025, Yazen's revenue surged 87% to nearly €29.4 million, with gross profits doubling to €16.5 million. Now treating over 37,000 active patients across seven countries, the company is eyeing further expansion into two more markets in 2026. Despite an EBITDA of –€5.7 million due to heavy growth investment, Yazen remains a leader in European obesity care.

Yazen presents an oral scientific abstract at the Nordic Obesity Meeting (NOM26), highlighting high-volume patient–caregiver interactions in a fully digital obesity care model.

Yazen’s work powering digital patient transformation for sustainable weight care is recognised by the HTN Now 2025/26 Awards in the category of Digital Patient Transformation.

Weight management patients show lasting alcohol reduction with health benefits extending beyond temporary Dry January abstinence, new research reveals.

The WHO released its first global guideline for GLP-1 obesity treatment, recognizing obesity as a chronic disease. Long-term care combined with therapy is key.

Yazen wins “Weight Loss Treatment of the Year 2025 award” for its innovative, evidence-based care helping over 47,000 patients achieve sustainable weight loss.

Yazen, Europe’s leading digital healthcare provider in obesity care, has been ranked as the second fastest-growing startup in Europe by the Sifted 250: Startup Europe Leaderboard 2025.

Yazen named the fastest-growing startup in the Nordics and Benelux in the Sifted 100 Leaderboard

At ECO 2025, Yazen presents data from 30,000+ patients, showing 16.6% weight loss after 18 months and 70% adherence to treatment with its digital care model.

Yazen partners with Withings to go beyond BMI for better health insights.

Yazen expands in Scandinavia through the acquisition of Danish company Medstart, which is established in Denmark and Norway. Together, they enhance care for people with obesity.

Yazen has secured €19.5 million in Series A funding to expand its GLP-1-based obesity treatment across Europe. The company combines medication with lifestyle support for sustainable weight loss results.